<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="167998">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01687699</url>
  </required_header>
  <id_info>
    <org_study_id>dohas01</org_study_id>
    <nct_id>NCT01687699</nct_id>
  </id_info>
  <brief_title>Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dialysis Outcomes Heart Failure Aldactone Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dialysis Outcomes Heart Failure Aldactone Study Group</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aldosterone receptor blockers reduce cardiac-related morbidity and mortality. Recently, we
      demonstrated that long-term low-dose spironolactone is clinically safe in many hemodialysis
      (HD) patients. In the present study, we assess whether low-dose spironolactone treatment
      reduces the high incidence of cardio- and cerebrovascular (CCV) morbidity and mortality in
      HD patients. The investigators' hypothesis is that aldosterone receptor blockade by
      spironolactone reduces the risk of both CCV morbidity and death among HD patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>cardio- and cerebrovascular events</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>death from all causes</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>End-stage Renal Failure</condition>
  <arm_group>
    <arm_group_label>spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <arm_group_label>spironolactone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemodialysis patients undergoing 4-hour-long HD thrice a week for at least 2 years

          -  With an average serum potassium level (immediately before dialysis on the first day
             of the week) of &lt;6.5 mEq/l over the previous 2 months

          -  With a 24-hour urine output of &lt;500 ml

        Exclusion Criteria:

          -  A history of noncompliance

          -  Unstable vascular access

          -  Hypotension

          -  Hepatic failure

          -  Active cancer

          -  Any life-threatening disease other than ESRD
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Shibukawa Clinic</name>
      <address>
        <city>Shizuoka</city>
        <zip>424-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19342857</url>
  </link>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 14, 2012</lastchanged_date>
  <firstreceived_date>September 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dialysis Outcomes Heart Failure Aldactone Study Group</investigator_affiliation>
    <investigator_full_name>Yoshihiro Matsumoto</investigator_full_name>
    <investigator_title>MD., PhD.</investigator_title>
  </responsible_party>
  <keyword>cardiovascular event</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>spironolactone</keyword>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
